Friday, 7 October, 2022
TopicPharmaceutical companies

Topic: Pharmaceutical companies

Pharma firms and diagnostics developers need to unite. They are catalysts for saving lives

Studies of drugs like remdesivir and hydroxychloroquine were underpowered and small, and the results were conflicting and, in many cases, inconclusive.

Molnupiravir helps in faster recovery of mild Covid patients, says Hetero after phase 3 trials

Hyderabad-based pharma company, Hetero, announced promising interim results of phase 3 trials and has approached DCGI for emergency use authorisation for the drug in India.

ZyCoV-D, the made-in-India Covid vaccine by Zydus Cadila, likely to hit markets in June

The Ahmedabad-based pharmaceutical firm plans to begin with manufacturing one crore doses a month. The vaccine is also being tested on adolescents.

Delhi HC asks govt to reply to PIL seeking firms to sell Remdesivir in domestic market

The plea claimed that there are more than 25 companies in India which manufacture the medicine, but only 6 to 8 are permitted to sell it in the domestic market.

Pharma industry warns of Covid drug shortages as raw materials prices surge 200%

Pharma firms say suspension of cargo from China has resulted hoarding, driving up prices of raw materials, seek govt intervention immediately.

After govt move to review remdesivir MRP, pharma firms say will cut it to under Rs 3,500/vial

Remdesivir is one of the most sought-after experimental drugs for the treatment of Covid patients and part of the country’s treatment protocol.

Cipla, Sun Pharma, Lupin on drug price watchdog’s new list of firms ‘overcharging consumers’

NPPA has issued a list of  ‘overcharging cases’ under litigation, which includes matters dating back to 1997 & those where firms have moved court against the allegations.

Why there’s no stopping the spectacular rise of this Indian pharma company

The optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chinese suppliers.

Pharma companies to cut prices of news drugs by 51% to access Chinese market

Patients will only need to pay a small fraction of the cost of these drugs as the lion’s share of the bill will be footed by China’s $373 billion national medical insurance fund.

High demand, strict inspections — how Biden’s presidency could impact India’s pharma sector

US is the biggest market for Indian pharmaceutical companies and Biden's presidency is expected to bring with it some favourbable changes that could have a long-ranging impact.

On Camera

YourTurn

Jaishankar to embark on his 1st visit to New Zealand from Oct 5

G20 has 5 daunting challenges and India’s presidency can turn this crisis into opportunity

India should highlight its leadership in low-cost vaccine tech, effective health immunisation delivery, generic pharmaceutical manufacturing, and solar energy.
Falguni Nayar, Nykaa's founder & CEO, and Sima Ganwani Ved, Apparel Group's founder & chairwoman, pose for a picture during a strategic alliance announcement in Mumbai, on 6 October 2022 | Reuters

Nykaa forge ties with Dubai’s Apparel Group to expand business in Gulf countries

Falguni Nayar, the online retailer founder and CEO, said the two companies would together build a multi-brand beauty retail business with Nykaa holding a 55% stake of the entity.

Defence

Rescue operation underway after an army aviation Cheetah helicopter flying in the forward area near Tawang crashed during a routine sortie Wednesday | ANI

Multiple military & civilian chopper crashes in past years highlight a disturbing trend for India

An Indian Army Aviation Cheetah helicopter crashed Wednesday. Several such crashes over past few yrs have jolted the military. Non-military sphere, too, has encountered many crashes.

India’s hijab supporters will lose even if they win SC battle. Because the real war is political

In a highly polarised time, cornered minorities tend to lean back and protect the roots and fundamentals of what is so dear to them. Politically, it can often be a bad trap.
×